Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 19/20 | 0.73 |
| ▸ | ROCK1 | Q13464 | 11/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32670276 | 1.00 | ROCK2 (0.73) | ROCK2ROCK1 | |
| SCHEMBL17038113 | 0.91 | ROCK2 (0.73) | ROCK2ROCK1 | |
| SCHEMBL15639035 | 0.89 | ROCK2 (0.70) | ROCK2ROCK1 | |
| SCHEMBL18114560 | 0.87 | ROCK2 (0.71) | ROCK2ROCK1 | |
| SCHEMBL17038111 | 0.85 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL17040778 | 0.85 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL24271475 | 0.84 | ROCK2 (0.63) | ROCK2ROCK1 | |
| SCHEMBL15639833 | 0.84 | ROCK2 (0.85) | ROCK2ROCK1 | |
| SCHEMBL32670211 | 0.84 | ROCK2 (0.85) | ROCK2ROCK1 | |
| SCHEMBL18114589 | 0.84 | ROCK2 (0.69) | ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034127-A1 | TREATMENT OF GVHD | KADMON CORP LLC (FR) | 2026-02-05 | — | — | US | disclosed |
| EP-4116293-A2 | RHO KINASE INHIBITORS | Kadmon Corporation, LLC (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-4116293-A2 | RHO KINASE INHIBITORS | Kadmon Corporation, LLC (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20220395501-A1 | TREATMENT OF GVHD | KADMON CORP LLC (US) | 2022-12-15 | — | — | US | disclosed |
| US-20220395501-A1 | TREATMENT OF GVHD | KADMON CORP LLC (US) | 2022-12-15 | — | — | US | disclosed |
| EP-2903618-B1 | RHO KINASE INHIBITORS | KADMON CORP LLC (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-2903618-B1 | RHO KINASE INHIBITORS | KADMON CORP LLC (US) | 2022-06-01 | — | — | EP | disclosed |
| US-11311541-B2 | Treatment of GVHD | KADMON CORPORATION, LLC (US) | 2022-04-26 | — | — | US | disclosed |
| US-11311541-B2 | Treatment of GVHD | KADMON CORPORATION, LLC (US) | 2022-04-26 | — | — | US | disclosed |
| CN-113773308-A | RHO kinase inhibitors | 卡德门企业有限公司 | 2021-12-10 | — | — | CN | disclosed |
| WO-2015157556-A1 | TREATMENT OF GVHD | KADMON CORPORATION, LLC (US) | 2015-10-15 | — | — | WO | disclosed |
| WO-2015157556-A1 | TREATMENT OF GVHD | KADMON CORPORATION, LLC (US) | 2015-10-15 | — | — | WO | disclosed |
| US-20150252025-A1 | RHO KINASE INHIBITORS | KADMON CORPORATION, LLC | 2015-09-10 | — | — | US | disclosed |
| US-20150252025-A1 | RHO KINASE INHIBITORS | KADMON CORPORATION, LLC | 2015-09-10 | — | — | US | disclosed |
| US-20150238601-A1 | TREATMENT OF OCULAR DISORDERS | KADMON CORPORATION, LLC | 2015-08-27 | — | — | US | disclosed |
| US-20150238601-A1 | TREATMENT OF OCULAR DISORDERS | KADMON CORPORATION, LLC | 2015-08-27 | — | — | US | disclosed |
| EP-2903645-A2 | TREATMENT OF OCULAR DISORDERS | Kadmon Corporation, LLC (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-2903618-A2 | RHO KINASE INHIBITORS | Kadmon Corporation, LLC (US) | 2015-08-12 | — | — | EP | disclosed |
| WO-2014055999-A2 | TREATMENT OF OCULAR DISORDERS | KADMON CORPORATION, LLC (US) | 2014-04-10 | — | — | WO | disclosed |
| WO-2014055996-A2 | RHO KINASE INHIBITORS | KADMON CORPORATION, LLC (US) | 2014-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034127-A1 | TREATMENT OF GVHD | ROCK2, RHOA, MYH2 | ROCK2 1/4885ROCK1 4/4885 |
| US-20150238601-A1 | TREATMENT OF OCULAR DISORDERS | ROCK2, KDR, FLT1 | ROCK2 1/4885ROCK1 5/4885 |
| US-20220395501-A1 | TREATMENT OF GVHD | ROCK2, ROCK1, RHOXF2 | ROCK2 1/4885ROCK1 2/4885 |
| US-11311541-B2 | Treatment of GVHD | ROCK2, ROCK1, RHOA | ROCK2 1/4885ROCK1 2/4885 |
| US-20150252025-A1 | RHO KINASE INHIBITORS | ROCK2, ROCK1, RHOA | ROCK2 1/4885ROCK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.